Company intelligence / Profile preview
Blue Lake Biotechnology
Athens, Georgia, United Statesbluelakebiotechnology.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
The company has completed Phase 1 trials for intranasal RSV and COVID vaccines, demonstrating excellent tolerability, cell-mediated immune responses, mucosal and antibody responses. Phase 2 trials were planned to start in the first half of 2023. The RSV vaccine has received Fast Track designation from the FDA.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Intranasal vaccinesPIV5-based vector vaccines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
CyanVac LLC (affiliate)
Beyond the preview
Go deeper on Blue Lake Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blue Lake Biotechnology.